Regulatory changes key: Hamburg

Share this article:
FDA commissioner Margaret Hamburg says it is important for the nation to strengthen its commitment to regulatory science so that it becomes a robust and respected discipline in the broader scientific enterprise. Her comments were made during an interview she gave to at the Cleveland Clinic healthcare summit in October.

Hamburg said that changes in the way regulatory science is viewed are “the key to ensuring that recent scientific discoveries that hold such promise are actually translated into new therapies and treatments.”

Asked what can be done to restore public trust in FDA, Hamburg said that increasing transparency will help break down the perception of FDA as a bureaucratic “black box.” She said it also needs to be recognized that we live in a world in which there will always be risks and crises, but there is much more than can be done to prevent such problems. “During a crisis we have to not be afraid to communicate rather than circle the wagons, which has happened before,” she said. “We have been taking a very clear-eyed look at past problems to learn from these mistakes.”

 On drug development, Hamburg said FDA is looking at ways to streamline the regulatory process and make it more effective. “There are real opportunities to apply emerging science to the regulatory process,” she said.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?